2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score
2015
Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia
Gupta N, Njei B. Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia. Journal Of Digestive Diseases 2015, 16: 683-688. PMID: 26147671, PMCID: PMC4824312, DOI: 10.1111/1751-2980.12273.Peer-Reviewed Original ResearchConceptsGiant cell hepatitisChronic lymphocytic leukemiaSyncytial giant cell hepatitisHigh-dose corticosteroidsHistory of chemotherapySuch confounding variablesPediatric populationDrug medicationAutoimmune diseasesLiver enzymesVirus infectionLymphocytic leukemiaHepatitisConfounding variablesPatientsViral particlesDiseaseAdultsSuch casesCorticosteroidsHypogammaglobulinemiaMedicationsChemotherapyMalignancyLeukemia